Listen

Press releases

Receive e-mail alerts

Interne link ProQR Announces Year End 2025 Operating and Financial Results
maart 12, 2026 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
maart 03, 2026 om 09:30 PM UTC
Interne link ProQR Announces Planned Changes to Board Composition
februari 09, 2026 om 01:00 PM UTC
Interne link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
januari 08, 2026 om 01:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders
december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference
november 21, 2017 om 12:00 PM UTC
Interne link ProQR Announces Results for the Third Quarter of 2017
november 20, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares
november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
november 09, 2017 om 12:00 PM UTC
Interne link ProQR to Present at EuroTIDES Conference
oktober 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Management Change and Key Promotions
oktober 26, 2017 om 11:00 AM UTC
Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
oktober 24, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference
oktober 06, 2017 om 11:00 AM UTC
Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
september 25, 2017 om 08:00 PM UTC
Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
september 21, 2017 om 11:05 AM UTC
Interne link ProQR to Present at Two Investor Conferences in September
september 21, 2017 om 11:00 AM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
september 19, 2017 om 11:00 AM UTC
Interne link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
september 12, 2017 om 11:00 AM UTC
Interne link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
september 05, 2017 om 11:00 AM UTC
Interne link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
augustus 29, 2017 om 11:00 AM UTC
Interne link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
augustus 28, 2017 om 11:00 AM UTC
Interne link ProQR Announces Results for the Second Quarter of 2017
augustus 16, 2017 om 11:00 AM UTC

Press releases

Interne link ProQR Announces Year End 2025 Operating and Financial Results

Interne link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Interne link ProQR Announces Planned Changes to Board Composition

Interne link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Interne link ProQR Announces Extraordinary General Meeting of Shareholders

Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference

Interne link ProQR Announces Results for the Third Quarter of 2017

Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Interne link ProQR Announces Proposed Public Offering of Ordinary Shares

Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Interne link ProQR to Present at EuroTIDES Conference

Interne link ProQR Announces Management Change and Key Promotions

Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference

Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

Interne link ProQR to Present at Two Investor Conferences in September

Interne link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

Interne link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Interne link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Interne link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial

Interne link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong

Interne link ProQR Announces Results for the Second Quarter of 2017